Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Biomarkers

Topic: Risk, prevention and care in population studies

Plain-language summary

The adaption of the battery for French-speaking subjects is reported as well as preliminary results of the on-going validation study of the GRECOG-VASC group [Clinical Trial NCT01339195]. The diagnostic accuracy of various screening tests is reviewed and showed an overall sub-optimal sensitivity (<0.8). The first studies showed that about a third of patients with VaD due to small vessel disease or with poststroke dementia have amyloid PET imaging suggestive of AD. Although results of these on-going studies will be available in few years, these data indicate that efforts should be done in clinical practice to reduce underdiagnosis of VCI; VCI should be examined using a specific protocol which will be fully normalized soon for French-speaking patients; the sub-optimal sensitivity of screening tests prompts to use a structured interview to grade Rankin scale and to perform systematically a comprehensive assessment in stroke patients at risk of VCI; poststroke dementia occurring after 3 months poststroke may be preventable by treatment of modifiable vascular risk factors and secondary prevention of stroke recurrence according to recent recommendations.

What this study adds

Evidence grade: Low

This is a narrative review. This paper reviews neuropsychological testing standards for vascular cognitive impairment and notes that about a third of some vascular dementia patients have amyloid PET suggestive of Alzheimer's disease. It is a review of assessment and diagnosis, not a study of treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Godefroy, O., GRECOG-VASC study group, Leclercq, C., Bugnicourt, J. M., Roussel, M., Moroni, C., et al. (2013). Neuropsychological assessment and cerebral vascular disease: the new standards. Revue neurologique. https://doi.org/10.1016/j.neurol.2013.07.009

Vancouver

Godefroy O, GRECOG-VASC study group, Leclercq C, Bugnicourt JM, Roussel M, Moroni C, et al. Neuropsychological assessment and cerebral vascular disease: the new standards. Revue neurologique. 2013. doi:10.1016/j.neurol.2013.07.009. PMID: 23999023.

BibTeX

@article{godefroy2013-23999023,
  author  = {Godefroy, O. and {GRECOG-VASC study group} and Leclercq, C. and Bugnicourt, J. M. and Roussel, M. and Moroni, C. and Quaglino, V. and Beaunieux, H. and others},
  title   = {{Neuropsychological assessment and cerebral vascular disease: the new standards}},
  journal = {Revue neurologique},
  year    = {2013},
  doi     = {10.1016/j.neurol.2013.07.009},
  pmid    = {23999023},
  url     = {https://doi.org/10.1016/j.neurol.2013.07.009}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This paper reviews neuropsychological testing standards for vascular cognitive impairment and notes that about a third of some vascular dementia patients have amyloid PET suggestive of Alzheimer's disease. It is a review of assessment and diagnosis, not a study of treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 34/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 34 of 100.34 of 100 points earned66 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Revue neurologique)
Journal's citation record 0 / 4 Revue Neurologique: journal h-index 70 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 21 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.4 citations a year over 15 year(s) since 2013
Impact for its field and year 2 / 6 Cited 1.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Frédéric Assal: h-index 38 (OpenAlex, whole career)
Institution's track record 1 / 3 Université de Lille: institution h-index 708 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23999023)
Free to read 0 / 2 Behind a paywall — scores zero
Total 34 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Biomarkers from nearby years

Also tagged “small”

900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →